Conference Proceedings

Randomized, doubleblind, phase 3 study of tucatinib or placebo in combination with T-DM1 for subjects with unresectable locally-advanced or metastatic HER2 breast cancer

Sara Hurvitz, Linda Vahdat, Nadia Harbeck, Antonio C Wolff, Sara M Tolaney, Sherene Loi, Norikazu Masuda, Cassie Dong, Luke Walker, Evelyn Rustia, Virginia Borges

Ongoing Clinical Trials | AMER ASSOC CANCER RESEARCH | Published : 2020